Helen V Hsieh Email & Phone Number

San Diego County, California, United States

Responsible for research and development of point-of-care medical diagnostics.

Greater Seattle Area

• Evaluate, transfer, and develop technologies for infectious disease diagnostics. Responsible for independently designing experiments, developing innovative and creative assays, developing standard, benchmarking.
• Plan and execute antibody screening experiments using an in-house robotic system for development of a COVID-19 rapid diagnostic test.
• Over 600 antibody pairs have been screened in 2 months.Malaria Antigen LFAs (2017-2020)
• Developed and optimized HRP2 and pLDH malaria LFAs. These LFAs are currently in development with a commercial partner.
• Developed highly sensitivity reference assays for use in our US-based laboratory.
• Researched, evaluated, and created SOPs for a commercial reference assay to be used at the field sites.

Greater Seattle Area

• Malaria Serology LFAs (2016-2017)
• Developed model serology systems for use in developing serology LFAs; this work was used to facilitate development of malaria serology LFAs and reference assays.
• The malaria serology LFAs performed well in comparison to the gold standard Luminex bead assay. Identified that a commonly used fusion protein could be problematic for use in tropical diseases diagnostics. Tuberculosis.
• Screened TB LAM antibody pairs for LFA development.
• Managed relationship with commercial vendor for development and production of initial prototype LFAs for field evaluation.

Research Triangle Park

• Invented, evaluated, transferred, and developed technologies for medical diagnostics. Notable accomplishments include inventing new diagnostic assays that were patented and/or commercialized, designing an in-house.
• Identified opportunity and co-authored successful grant application "Simple and Rapid Diagnosis of Preeclampsia" for the Saving Lives at Birth 2014 competition. http://savinglivesatbirth.net/summaries/285
• Designed innovative nanoparticle assays as well as standard diagnostic assays (e.g. immunoassays, ELISA, lateral flow). Assay methods were incorporated into the new product line, the BD Veritor™ System.
• Designed and executed scale-up of diagnostic test units by successfully assembling an in-house bulk production line complete with GMP SOPs. This production line produced up to 2000 individual units per lot, leading to.
• Evaluated possible markets for BD nanotechnology. GLUCOSE MONITORING (2000-2006)
• Co-invented initial detection and attachment chemistries for a Continuous Glucose Monitoring (CGM) device. CELL BIOLOGY (1999-2000)

Chapel Hill, NC

Advisor-Nancy L Thompson

Phd, Chemistry

Thesis: Investigation of the Interaction Between IgG and Mouse Fc gamma Receptor Using Total Internal Reflection Fluorescence Microscopy

Ba, Chemistry